AB
MRSN

Amalgamated Bank’s Mersana Therapeutics MRSN Stock Holding History

Amalgamated Bank’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-151
Closed -$1K – 3090
2025
Q1 		$1K Hold
151
– – ﹤0.01% 2920
2024
Q4 		$5K Hold
151
– – ﹤0.01% 2738
2024
Q3 		$7K Hold
151
– – ﹤0.01% 2629
2024
Q2 		$8K Hold
151
– – ﹤0.01% 2564
2024
Q1 		$17K Sell
151
-320
-68% -$31.8K ﹤0.01% 2203
2023
Q4 		$27K Sell
471
-36
-7% -$1.45K ﹤0.01% 2518
2023
Q3 		$16K Hold
507
– – ﹤0.01% 2752
2023
Q2 		$42K Buy
507
+131
+35% +$19.2K ﹤0.01% 2398
2023
Q1 		$39K Sell
376
-97
-21% -$13.6K ﹤0.01% 2405
2022
Q4 		$69K Buy
473
+15
+3% +$2.54K ﹤0.01% 2296
2022
Q3 		$77K Buy
458
+13
+3% +$2.11K ﹤0.01% 2269
2022
Q2 		$51K Buy
445
+13
+3% +$1.22K ﹤0.01% 2474
2022
Q1 		$43K Sell
432
-33
-7% -$3.85K ﹤0.01% 2547
2021
Q4 		$72K Sell
465
-9
-2% -$1.75K ﹤0.01% 2090
2021
Q3 		$112K Sell
474
-7
-1% -$2.04K ﹤0.01% 2067
2021
Q2 		$163K Buy
+481
New +$182K ﹤0.01% 2062
2021
Q1 		– Sell
-333
Closed -$222K – 1616
2020
Q4 		$222K Buy
+333
New +$185K 0.01% 1394

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Amalgamated Bank's MRSN Position: Q2 2025 in Review

Amalgamated Bank sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 151 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in MRSN in Q4 2020 and held it in 17 quarters. The position peaked at $222K in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Amalgamated Bank reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 151 Mersana Therapeutics shares in Q2 2025, an estimated $1K.
  • Amalgamated Bank first reported a position in Mersana Therapeutics in Q4 2020 and held it in 17 quarters.
  • Amalgamated Bank's Mersana Therapeutics position peaked at $222K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.